Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SURE-02 perioperative pembrolizumab plus sacituzumab govitecan in cisplatin-ineligible or cisplatin-refusing muscle-invasive bladder cancer
2020-004876-16Phase 2Active
- Sponsor
- IRCCS Ospedale San Raffaele
- Start
- Aug 2021
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of pembrolizumab and sacituzumab govitecan in muscle-invasive bladder cancer (MIBC) and transitional cell carcinoma of the bladder (TCC), sponsored by IRCCS Ospedale San Raffaele. Primary endpoint: Pathological complete response. Started Aug 2021; status: active.
02
Drugs
pembrolizumabsacituzumab govitecan
03
Conditions
muscle-invasive bladder cancer (MIBC)transitional cell carcinoma of the bladder (TCC)
Beyond the preview
Go deeper on 2020-004876-16.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-004876-16.